N-(4-aminophenyl)-2-cyanoacetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-aminophenyl)-2-cyanoacetamide
• 英文别名: N-(4-Aminophenyl)-2-cyanoacetamide
• 化学式: C₉H₉N₃O
• 分子量: 175.19
• InChiKey: XDJIXNCLHCOEDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-aminophenyl)-2-cyanoacetamide 在 哌啶 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 N-(4-(((2-chloroquinolin-3-yl)methylene)amino)phenyl)-2-imino-2H-chromene-3-carboxamide
  参考文献：
  名称：

  Carboxamide appended quinoline moieties as potential anti-proliferative agents, apoptotic inducers and Pim-1 kinase inhibitors

  摘要：

  DOI：

  10.1007/s00044-021-02765-y
• 作为产物：
  描述：

  1-cyanoacetyl-3,5-dimethylpyrazole 、 对苯二胺 以 甲苯 为溶剂， 反应 0.25h， 以93%的产率得到N-(4-aminophenyl)-2-cyanoacetamide
  参考文献：
  名称：

  Transmonocyanoacetylation of phenylenediamines: a simple and efficient synthesis of novel N-(aminophenyl)-2-cyanoacetamides and their derivatives

  摘要：

  Herein, we report a simple and efficient method for the transmonocyanoacetylation of phenylenediamines using inexpensive, commercially available 1-cyanoacetyl-3,5-dimethylpyrazole as a cyanoacetylating agent. This method provides operationally simple and efficient access to N-(aminophenyl)-2-cyanoacetamides under mild conditions with short reaction times. Also, a series of novel N-(functionalized phenyl)-2-cyanoacetamide derivatives have been synthesized through the reaction of N-(4-aminophenyl)-2-cyanoacetamide with various electrophiles, such as carbonyl, acyl chloride, and isothiocyanate derivatives. In all cases, good yields of products were obtained and reaction times were significantly reduced compared with similar reactions. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.11.098

文献信息

• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• NOVEL KINASE INHIBITORS
  申请人：ORIGENIS GMBH

  公开号：US20150259340A1

  公开（公告）日：2015-09-17

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及式（I）的新型化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗各种疾病。这些疾病包括自身免疫性疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS
  申请人：ORIGENIS GMBH

  公开号：US20150266882A1

  公开（公告）日：2015-09-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及化合物(I)的新型化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病方面有应用。这些疾病包括自身免疫疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼病、传染病和激素相关疾病。
• A novel of quinoxaline derivatives tagged with pyrrolidinyl scaffold as a new class of antimicrobial agents: Design, synthesis, antimicrobial activity, and molecular docking simulation
  作者：Mostafa M. Abdelgalil、Yousry A. Ammar、Gameel A.M. Elhag Ali、Ali Kh. Ali、Ahmed Ragab

  DOI：10.1016/j.molstruc.2022.134443

  日期：2023.2

  substitution reaction. The structure of quinoxaline derivatives was confirmed by IR, 1H NMR, and 13C NMR spectra. The antimicrobial activity of quinoxaline derivatives 4–10 varied from good to potency against the tested strains. The quinoxaline derivatives 4, 6, and 7 exhibited excellent activity, especially against B. pumilis and E. cloacae, with MIC values of (7.8, 15.6, and 3.91 µg/mL) and (15.6, 7.8, and

  在全球范围内，由于抗生素耐药性已达到高水平，传染病变得越来越难治疗。此外，有必要开发新的治疗方案来对抗临床环境中日益增长的抗菌素耐药性。通过亲核取代反应合成了新的 3-(pyrrolidin-1-yl)quinoxaline 衍生物4-10通过醚或胺键与 C2 上的不同取代基共轭。喹喔啉衍生物的结构通过 IR、1 H NMR 和13 C NMR 光谱证实。喹喔啉衍生物4-10对测试菌株的抗菌活性从良好到有效不等。喹喔啉衍生物4、6和7表现出优异的活性，尤其是对短小芽孢杆菌和阴沟肠杆菌，与环丙沙星相比，MIC 值为（7.8、15.6 和 3.91 µg/mL）和（15.6、7.8 和 15.6 µg/mL） （7.8 和 15.6 µg/mL）。此外，在 C2 处具有不同甲亚胺部分的杂合喹喔啉显示出中等至良好的抗菌活性，但甲亚胺9和10对大肠杆菌和粪链球菌的 MIC 值分别与环丙沙星 15.6